Search Results for: ustr

As part of a partial response to FOIA request, USTR has provided KEI with copies of 13 letters sent by members of Congress, from July 27, 2011 to August 8, 2013, on the topic of biologic drug test data provisions in the TPP negotiation. We had obtained several but not all of these letters earlier from a variety of sources, including from PhRMA’s web page — where some had been proudly displayed. (See link below).

Were there letters on the other side? Yes, three. (see below).

With the FOIA request, we have also obtained the responses to the letters.

Continue Reading →

The attached letter, dated April 10, 2014 and signed by a bipartisan group of 32 members of the House of Representatives, asks USTR to elevate Canada to the Special 301 “priority watch list,” for “violation of their international obligations” for not granting enough patents on “innovative medicines.” According to the members of Congress signing the letter, Canada is in violation of its WTO TRIPS obligations. Continue Reading →

Claire Cassedy did this interview at the KEI offices, following the February 24, 2014 USTR hearing on the Special 301.
Continue Reading →

Here is the REVISED agenda for the Special 301 hearing on February 24. Public Citizen has been added to the list of witnesses, and USTR now lists the names of the speakers for the various trade associations. Unlike recent years, the level of participation by major trade organizations is significant.

SPECIAL 301 PUBLIC HEARING
February 24, 2014 – 10:00 a.m.

Office of the United States Trade Representative
1724 F Street, NW
Washington, D.C. 20508

The Special 301 Hearing is open to the public. Members of the press are welcome to attend.
Continue Reading →